Cos (e.g., Cos-7, Etc.) Patents (Class 435/365)
Expressing recombinant lymphokine, interferon, hormone, growth factor or morphogen (Class 435/365.1)
-
Publication number: 20140323348Abstract: Disclosed are methods of promoting and/or enhancing G-Protein Coupled Receptor (GPCR) localization to the cell membrane and/or cell surface; methods of promoting and/or enhancing GPCR functional expression; and methods and assays for screening or identifying ligands (e.g., agonists or antagonists) that bind GPCRs. Also provided are vectors, recombinant cells, and stable cell lines for use in the methods and assays.Type: ApplicationFiled: November 30, 2012Publication date: October 30, 2014Inventors: Hiroaki Matsunami, Yue Jiang, Ming-Shan Chien
-
Publication number: 20140315804Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.Type: ApplicationFiled: March 13, 2014Publication date: October 23, 2014Applicant: GENZYME CORPORATIONInventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
-
Publication number: 20140314758Abstract: Immunogenic peptides from tumor associated stromal cell antigens, including combinations of such peptides, are disclosed herein. In some examples the peptides are useful for methods of eliciting an immune response. In additional examples the peptides are useful for methods of treating cancer. Methods for decreasing vascularization of a tumor using a Protein Delta Homolog 1 (DLK1) protein or a nucleic acid encoding the protein are also disclosed.Type: ApplicationFiled: November 15, 2012Publication date: October 23, 2014Applicant: University of Pittsburgh- Of the Commonwealth System of Higher EducationInventors: Walter J. Storkus, Anamika Bose, Jennifer Lynn Taylor, Xi Zhao, Devin B. Lowe
-
Publication number: 20140310830Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.Type: ApplicationFiled: December 12, 2013Publication date: October 16, 2014Inventors: Feng ZHANG, Le CONG, Fei RAN
-
Patent number: 8858928Abstract: The present invention provides compositions comprising retroviral vectors, transduced cells, and methods of using the same for gene therapy. In particular, the present invention relates to lentiviral vectors and cells transduced with those vectors to provide gene therapy to subjects having an adrenoleukodystrophy and/or adrenomyeloneuropathy.Type: GrantFiled: June 8, 2012Date of Patent: October 14, 2014Assignee: bluebird bio, Inc.Inventors: Maria Joann Denaro, Mitchell Howard Finer, Gabor Veres, Julian Down
-
Patent number: 8853154Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: GrantFiled: September 12, 2013Date of Patent: October 7, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.
-
Publication number: 20140295457Abstract: The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.Type: ApplicationFiled: October 11, 2012Publication date: October 2, 2014Inventors: Mark Broenstrup, Claudia Koenig, Luigi Toti, Joachim Wink, Wulf Leuschner, Johann Gassenhuber, Rolf Müller, Silke Wenzel, Tina Binz, Carsten Volz
-
Publication number: 20140295502Abstract: The present invention generally relates to methods of making cDNA molecules and cDNA libraries. The invention also relates to cDNA molecules and cDNA libraries produced according to these methods, as well as to vectors and host cells containing such cDNA molecules and libraries. The invention also relates to kits for making the cDNA molecules and libraries of the invention.Type: ApplicationFiled: May 13, 2014Publication date: October 2, 2014Inventors: Wu-Bo LI, Joel Jessee, Christian Gruber
-
Publication number: 20140295544Abstract: The present invention relates to fluorescent proteins, in particular green fluorescent proteins (GFPs), with increased activity in cells, and thus increased signal strength. A further aspect of the present invention relates to the use of peptides for increasing the expression and/or stability of a protein in a cell.Type: ApplicationFiled: June 13, 2014Publication date: October 2, 2014Inventor: Khalid S. Abu KHABAR
-
Publication number: 20140298505Abstract: The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease.Type: ApplicationFiled: June 6, 2012Publication date: October 2, 2014Inventor: Ralf Kühn
-
Patent number: 8846373Abstract: The present invention relates to new methods to promote sialylation of glycoconjugates, including recombinant glycoproteins, in glycoconjugate production systems. The invention relates to methods to promote efficient glycoconjugate sialylation in recombinant expression systems, by providing simpler and more economical ways to produce large intracellular pools of sialic acid precursors. The invention is directed to nucleic acids, vectors, and cells harboring vectors comprising nucleic acids encoding enzymes involved in the synthesis of sialic acid precursors, and cells harboring these nucleic acids in combination with nucleic acids encoding glycosyltransferases, including sialyltransferases, to facilitate the production of humanized recombinant glycoproteins in bacterial, fungal, plant, and animal cell expression systems.Type: GrantFiled: July 27, 2012Date of Patent: September 30, 2014Assignee: The University of WyomingInventors: Christoph Geisler, Donald Jarvis
-
Patent number: 8846603Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: GrantFiled: March 11, 2011Date of Patent: September 30, 2014Assignee: Synageva Biopharma Corp.Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
-
Publication number: 20140272932Abstract: The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.Type: ApplicationFiled: December 23, 2013Publication date: September 18, 2014Applicant: Abbott LaboratoriesInventors: A. Scott Muerhoff, Christopher Marohnic, Larry Birkenmeyer, John Prostko, Felisha Bogdan, Robin Gutierrez
-
Publication number: 20140274782Abstract: Methyl-lysine affinity reagents created by engineering the 3×MBT methyl-lysine binding domain repeat of lethal (3) malignant brain tumor-like protein 1 (L3MBTL1) are disclosed. In particular, the invention relates to affinity reagents and affinity chromatography media comprising the 3×MBT domain repeat and methods of using such affinity reagents in detection, purification, and proteomic profiling of methylated proteins and peptides.Type: ApplicationFiled: March 15, 2014Publication date: September 18, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Scott M. Carlson, Or Gozani, Kaitlyn E. Moore
-
Publication number: 20140273097Abstract: Disclosed herein are methods and compositions for inactivating a FUT8 gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.Type: ApplicationFiled: May 28, 2014Publication date: September 18, 2014Applicant: Sangamo BioSciences, Inc.Inventors: Trevor Collingwood, Gregory J. Cost
-
Publication number: 20140274874Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: AMGEN INC.Inventors: Randal R. KETCHEM, Jason Charles O'NEILL, Jeonghoon SUN
-
Publication number: 20140273089Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The inventio further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: AMGEN, INC.Inventors: Christiaan M. Saris, Sharon X. Mu, Min Xia, Thomas Charles Boone, Todd Covey
-
Publication number: 20140274909Abstract: The disclosure provides a chimeric antigen receptor (CAR) comprising a) an antigen binding domain of HA22, a transmembrane domain, and an intracellular T cell signaling domain; or b) an antigen binding domain of BL22, a transmembrane domain, and an intracellular T cell signaling domain comprising CD28 and/or CD137. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: October 19, 2012Publication date: September 18, 2014Inventors: Rimas J. Orentas, Crystal L. Mackall, Ira H. Pastan
-
Publication number: 20140273096Abstract: The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.Type: ApplicationFiled: April 9, 2014Publication date: September 18, 2014Applicant: CSL Behring GmbHInventors: Stefan SCHULTE, Thomas WEIMER, Hubert METZNER
-
Publication number: 20140273206Abstract: The current disclosure provides a method for the creation of a high-density cryopreserved cell bank using perfusion culture techniques and non-centrifugal concentration of cells. Methods of production using this high-density cryopreserved cell bank are also provided.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Genzyme CorporationInventors: Xiaoxia JIN, Haodi DONG, Claudia BUSER
-
Publication number: 20140255990Abstract: The present invention provides isolated polynucleotides that can serve as translation enhancing elements and their use in protein expression reagents and methods.Type: ApplicationFiled: October 26, 2012Publication date: September 11, 2014Applicant: Arizona Board of RegentsInventors: John Chaput, Bertram Jacobs, Brian Wellensiek, Julia Flores
-
Publication number: 20140248397Abstract: A variant polypeptide having alpha-amylase activity, wherein the variant has an amino acid sequence which, when aligned with the alpha-amylase comprising the sequence set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid residue corresponding to any of amino acids 4, 6, 13, 14, 15, 16, 20, 45, 47, 51, 54, 61, 68, 69, 70, 71, 72, 73, 74, 75, 77, 78, 80, 82, 87, 88, 94, 95, 100, 103, 104, 117, 124, 125, 126, 128, 130, 133, 134, 136, 143, 144, 146, 168, 174, 177, 178, 183, 186, 188, 189, 190, 194, 195, 199, 200, 201, 204, 207, 210, 214, 217, 219, 222, 225, 227, 233, 234, 235, 236, 240, 251, 252, 254, 258, 259, 260, 261, 262, 263, 264, 266, 267, 269, 271, 273, 281, 282, 283, 284, 286, 288, 299, 322, 323, 325, 327, 328, 331, 334, 350, 356, 358, 367, 370, 371, 374, 377, 378, 388, 391, 414, 421, 422, 445, 450, 467, 488, 505, 536, 548, 583, 588, 603, 637, 648, 651, 652, 660, 676, 677, said positions being defined with reference to SEQ ID NO: 2 and wherein the variant has one or more altered prType: ApplicationFiled: March 15, 2013Publication date: September 4, 2014Applicant: DSM IP ASSETS B.V.Inventors: Rene Marcel DE JONG, Hanna Elisabet ABBAS
-
Patent number: 8822180Abstract: There are provided a DNA construct comprising a suppressor tRNA gene of a non-eukaryote containing no internal promoter functioning in a eukaryotic cell, and a eukaryotic or bacteriophage promoter linked at the 5? end of the tRNA gene, a method for synthesizing a suppressor tRNA by using the DNA construct, and a process for producing protein incorporating a non-natural amino acid by using the same.Type: GrantFiled: April 30, 2012Date of Patent: September 2, 2014Assignee: RikenInventors: Shigeyuki Yokoyama, Kensaku Sakamoto, Nobumasa Hino, Takahito Mukai, Takatsugu Kobayashi
-
Patent number: 8822181Abstract: A method for forming a fusion protein that is expressed as a recombinant protein body-like assembly in host eukaryotic cells and organisms other than higher plants as host systems is disclosed. More particularly, peptides and proteins are fused to protein sequences that mediate the induction of recombinant protein body-like assembly (RPBLA) formation, are stably expressed and accumulated in these host cells after transformation with an appropriate vector. Methods for preparing the fusion protein are also disclosed.Type: GrantFiled: November 29, 2005Date of Patent: September 2, 2014Assignee: ERA Biotech S.A.Inventors: Margarita Torrent, Miriam Bastida, Pablo Marzábal, Blanca Llompart, Ma Dolores Ludevid
-
Publication number: 20140242692Abstract: The present invention relates to cellular proteins that are involved in toxicity and infection or are otherwise associated with the life cycle of one or more pathogens.Type: ApplicationFiled: December 11, 2011Publication date: August 28, 2014Inventors: Donald Rubin, Dana Borden Lacy
-
Publication number: 20140235693Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpinal gene, and methods of using such dsRNA compositions to inhibit expression of Serpinal. In one embodiment, an iRNA for inhibiting expression of a Serpinal gene includes at least two sequences that are complementary to each other. The iRNA includes a sense strand having a first sequence and an antisense strand having a second sequence. The antisense strand includes a nucleotide sequence that is substantially complementary to at least part of an mRNA encoding Serpinal, and the region of complementarity is 30 nucleotides or less, and at least 15 nucleotides in length. Generally, the iRNA is 19 to 24, e.g., 19 to 21 nucleotides in length.Type: ApplicationFiled: June 22, 2012Publication date: August 21, 2014Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt
-
Publication number: 20140237632Abstract: Nucleic acid compositions encoding rapidly maturing fluorescent proteins, as well as non-aggregating versions thereof (and mutants thereof) as well as the proteins encoding the same, are provided. The proteins of interest are proteins that are fluorescent, where this feature arises from the interaction of two or more residues of the protein. The subject proteins are further characterized in that, in certain embodiments, they are mutants of wild type proteins that are obtained either from non-bioluminescent Cnidarian, e.g., Anthozoan, species or are obtained from Anthozoan non-Pennatulacean (sea pen) species. In certain embodiments, the subject proteins are mutants of wild type Discosoma sp. “red” fluorescent protein. Also of interest are proteins that are substantially similar to, or mutants of, the above specific proteins. Also provided are fragments of the nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and transgenic cells and organisms.Type: ApplicationFiled: January 21, 2014Publication date: August 21, 2014Inventors: BROOKE BEVIS, BENJAMIN GLICK
-
Publication number: 20140228238Abstract: The present application provides novel human genes A7322, whose expression is markedly elevated in breast cancer. The present application also provides human genes F3374 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. The invention features methods of screening for modulators of the kinase activity of PBK/TOPK. The invention further provides methods of screening for agents to prevent or treat cancer, such as breast cancer.Type: ApplicationFiled: January 23, 2014Publication date: August 14, 2014Applicant: ONCOTHERAPY SCIENCE, INC.Inventors: Yusuke NAKAMURA, Toyomasa KATAGIRI, Shuichi NAKATSURU
-
Publication number: 20140220060Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.Type: ApplicationFiled: December 26, 2013Publication date: August 7, 2014Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.Inventors: Jan ZUR MEGEDE, Susan BARNETT, Ying LIAN, Susan ENGELBRECHT, Estrelita Janse VAN RENSBERG, Thomas J. SCRIBA
-
Publication number: 20140221613Abstract: The purpose of the present invention is: to provide an excellent protein which is further reduced in the binding property to an Fc region of an immunoglobulin and/or the binding property to an Fab region of the immunoglobulin in a weakly acidic region compared with that of a protein containing an extracellular domain of wild-type protein G, and which still keeps a high antibody-binding activity in a neutral region; and to capture and collect an antibody readily using the protein without denaturating the antibody.Type: ApplicationFiled: August 3, 2012Publication date: August 7, 2014Inventors: Shinya Honda, Hiroyuki Matsumaru, Hideki Watababe, Chuya Yoshida
-
Publication number: 20140212928Abstract: Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences.Type: ApplicationFiled: March 6, 2014Publication date: July 31, 2014Applicant: Sangamo BioSciences, Inc.Inventor: Jianbin Wang
-
Publication number: 20140213511Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.Type: ApplicationFiled: January 27, 2014Publication date: July 31, 2014Inventors: Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar
-
Publication number: 20140212406Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.Type: ApplicationFiled: September 7, 2012Publication date: July 31, 2014Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Denis Viven, Jerome Parcq
-
Publication number: 20140206620Abstract: The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.Type: ApplicationFiled: March 21, 2014Publication date: July 24, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Steven A. Rosenberg, Richard A. Morgan, Timothy L. Frankel
-
Publication number: 20140206599Abstract: IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpha and common gamma chain complexes (Type 1) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions.Type: ApplicationFiled: March 26, 2014Publication date: July 24, 2014Applicant: Janssen Biotech, Inc.Inventors: Michael Baumann, Gaby Tresch, Steven Jacobs, Karyn O'Neil
-
Publication number: 20140206037Abstract: A vector production system is provided. The system comprises recombinant cells designed to encode at least a first recombinase under the control of an inducible promoter and the cells include an expression vector encoding a nucleic acid of interest within the regulatory elements of the expression vector which are flanked on either side by a target sequence for at least the first recombinase. The vector production system provides an efficient one-step process for producing linear or circular covalently closed vectors that incorporate a nucleic acid sequence of interest.Type: ApplicationFiled: November 22, 2013Publication date: July 24, 2014Inventors: Roderick A Slavcev, Nafiseh Nafissi
-
Publication number: 20140201855Abstract: Described are mutant luciferases, nucleic acids that encode them, cells and animals expressing them, methods of use thereof, and kits.Type: ApplicationFiled: February 9, 2012Publication date: July 17, 2014Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Stephen C. Miller, David Mofford, Katryn Harwood
-
Publication number: 20140193856Abstract: The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention utilizes recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue organ or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or target gene in an organism when introduced thereto are also provided.Type: ApplicationFiled: December 20, 2013Publication date: July 10, 2014Applicant: Commonwealth Scientific and Industrial Research OrganisationInventors: Michael Wayne Graham, Robert Norman Rice, Peter Michael Waterhouse
-
Publication number: 20140194355Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: ApplicationFiled: March 11, 2014Publication date: July 10, 2014Applicant: Amgen Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Publication number: 20140194365Abstract: C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.Type: ApplicationFiled: March 12, 2014Publication date: July 10, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Carol A. Feghali-Bostwick, Yukie Yamaguchi
-
Publication number: 20140186395Abstract: Described are methods for determining the permissiveness of a cell for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular, for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Further described are methods and compositions related to the generation of host cells permissive for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular, for PRRSV. Methods of utilzing the cells thus identified or thus generated, in preparing a culture of a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, as well as the use of the virus for the purpose of vaccine production or diagnosis, are also described.Type: ApplicationFiled: March 13, 2013Publication date: July 3, 2014Applicant: Universiteit GentInventors: Peter Delputte, Hans Nauwynck, Hanne Van Gorp
-
Publication number: 20140186380Abstract: Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies. Also disclosed are methods of using the binding agents for the treatment of diseases such as cancer.Type: ApplicationFiled: December 4, 2013Publication date: July 3, 2014Applicant: OncoMed Pharmaceuticals Inc.Inventors: Austin L. GURNEY, Fumiko Takada Axelrod
-
Publication number: 20140186887Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.Type: ApplicationFiled: October 28, 2013Publication date: July 3, 2014Applicant: IMMUNEX CORPORATIONInventor: DIRK M. ANDERSON
-
Publication number: 20140179595Abstract: Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication.Type: ApplicationFiled: July 20, 2012Publication date: June 26, 2014Applicants: UNIVERSITY OF SOUTH CAROLINA, University of Pittsburgh- Of the Commonwealth System of Higher EducationInventors: Tianyi Wang, Shufeng Liu, Fan Daping
-
Publication number: 20140178985Abstract: The invention relates generally to beta (1,4)-galactosyltransferase I mutants having altered donor and acceptor specificities, and methods of use thereof. In addition, the invention relates to methods for synthesizing oligosaccharides using the beta (1,4)-galactosyltransferase I mutants and to using the beta (1,4)-galactosyltransferase I mutants to conjugate agents, such as therapeutic agents or diagnostic agents, to acceptor molecules.Type: ApplicationFiled: July 16, 2013Publication date: June 26, 2014Inventors: Pradman K. Qasba, Boopathy Ramakrishnan, Elizabeth Boeggeman
-
Publication number: 20140171493Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: January 23, 2014Publication date: June 19, 2014Applicants: ALTIF LABORATORIES, TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCEInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20140162358Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown, and to mutated (non-endogenous) versions of the human. GPCRs for evidence of constitutive activity.Type: ApplicationFiled: June 27, 2013Publication date: June 12, 2014Inventors: RUOPING CHEN, ZHI LIANG CHU, HUONG T. DANG, KEVIN P. LOWITZ, CAMERON PRIDE
-
Publication number: 20140161788Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.Type: ApplicationFiled: November 27, 2013Publication date: June 12, 2014Applicant: BioMarin Pharmaceutical Inc.Inventors: Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
-
Publication number: 20140162296Abstract: The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.Type: ApplicationFiled: March 14, 2013Publication date: June 12, 2014Inventors: Katherine E. Varley, Richard M. Myers, Brian S. Roberts, Jason Gertz, Donald J. Buchsbaum, Andres Forero-Torres, Albert F. LoBuglio
-
Publication number: 20140162936Abstract: The present invention relates to a polypeptide binding to a chymase (EC 3, 4, 21,39), wherein the polypeptide comprises or consists of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X1)A(X2)(X3)(X4)(X5) (X6)LSFHKGEKFQIL(X7 (X8)(X9)(X10) (X11)(X12)G(X13)(X14)WEARSLTTGETGYIPSNYVAPVDSIQ (SEQ ID NO: 1), wherein (X1) is R, N, Q, E, K, H, S, T, C, or D; (X2) is E, T, D, Q, L, P, A, S, C, M, N, E, G, A, V or I; (X3) is R, T, H, N, K, S, C, N or Q; (X4) is S, W, T, C, N, Q, For Y; (X5) is T, H, L, F, C, S, M, N, Q, R, K, G, A, V, I, P, Y or W; (X6) is D, Q, H, E, S, T, C, N, R or K; (X7) is D, N, R, E, Q, S, T, C, K or D; (X8) is M, W, G, F, A, S, T, C, S, N, Q, Y, V, L, I or P; (X9) is T, H, S, D, C, N, Q, R, K, E or absent; (X10) is V, T, Q, G, A, L, I, P, S, C, M, N or absent; (X11) is P, A, D, G, K, V, L, I, E, R, M, H or absent; (X12) is N, V, P, I, E, T, S, A, G, L, C, M, Q or D; (X13) is D, E, T, P, G, A, V, L, I, S, C, M, N or Q, and (X14) is W, Y, L, G, A, V, I, P, M, or F; (b)Type: ApplicationFiled: April 24, 2012Publication date: June 12, 2014Applicant: COVAGEN AGInventors: Simon Brack, Sarah Batey, Dragan Grabulovski, Julian Bertschinger, Daniel Schlatter, Jörg Benz, David Banner, Michael Hennig